Immuneering Corporation NASDAQ:IMRX

Founder-led company

Immuneering stock price today

$3.38
+1.04
+45.06%
Financial Health
0
1
2
3
4
5
6
7
8
9

Immuneering stock price monthly change

+87.90%
month

Immuneering stock price quarterly change

+87.90%
quarter

Immuneering stock price yearly change

-68.51%
year

Immuneering key metrics

Market Cap
63.03M
Enterprise value
255.95M
P/E
-6.07
EV/Sales
807.54
EV/EBITDA
-5.25
Price/Sales
1021.44
Price/Book
2.94
PEG ratio
-0.27
EPS
-1.86
Revenue
N/A
EBITDA
-13.97B
Income
-54.17M
Revenue Q/Q
N/A
Revenue Y/Y
-100%
Profit margin
-15937.29%
Oper. margin
-16325.96%
Gross margin
50.11%
EBIT margin
-16325.96%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Immuneering stock price history

Immuneering stock forecast

Immuneering financial statements

Immuneering Corporation (NASDAQ:IMRX): Profit margin
Jun 2023 94.41M -12.18M -12.91%
Sep 2023 0 -12.59M
Dec 2023 -94.41M -15.08M 15.98%
Mar 2024 0 -14.30M
Immuneering Corporation (NASDAQ:IMRX): Analyst Estimates
Mar 2024 0 -14.30M
Sep 2025 0 -14.48M
Oct 2025 0 -13.06M
Dec 2025 0 -14.09M
  • Analysts Price target

  • Financials & Ratios estimates

Immuneering Corporation (NASDAQ:IMRX): Earnings per share (EPS)
2023-11-09 -0.51 -0.43
2024-03-01 -0.48 -0.52
2024-05-07 -0.45 -0.49
Immuneering Corporation (NASDAQ:IMRX): Debt to assets
Jun 2023 124895330 9.79M 7.84%
Sep 2023 113880939 9.86M 8.66%
Dec 2023 102584538 12.00M 11.71%
Mar 2024 87982840 9.26M 10.52%
Immuneering Corporation (NASDAQ:IMRX): Cash Flow
Jun 2023 -10.74M 9.16M 28.17M
Sep 2023 -12.02M -23.97M 21.44K
Dec 2023 -11.77M 3.13M 7.83K
Mar 2024 -15.49M 21.39M 979.92K

Immuneering alternative data

Immuneering Corporation (NASDAQ:IMRX): Employee count
Aug 2023 68
Sep 2023 66
Oct 2023 66
Nov 2023 66
Dec 2023 67
Jan 2024 67
Feb 2024 67
Mar 2024 68
Apr 2024 68
May 2024 68
Jun 2024 65
Jul 2024 65

Immuneering other data

7.68% -36.74%
of IMRX is owned by hedge funds
2.02M -9.69M
shares is hold by hedge funds

Immuneering Corporation (NASDAQ:IMRX): Insider trades (number of shares)
Period Buy Sel
Mar 2024 197083 909091
Apr 2024 0 400000
Transaction Date Insider Security Shares Price per share Total value Source
Sale
CORMORANT ASSET MANAGEMENT, LP 10 percent owner
Class A Common Stock 100 $3.07 $307
Sale
CORMORANT ASSET MANAGEMENT, LP 10 percent owner
Class A Common Stock 300 $3.07 $920
Sale
CORMORANT ASSET MANAGEMENT, LP 10 percent owner
Class A Common Stock 100 $3.05 $305
Sale
CORMORANT ASSET MANAGEMENT, LP 10 percent owner
Class A Common Stock 600 $3.03 $1,818
Sale
CORMORANT ASSET MANAGEMENT, LP 10 percent owner
Class A Common Stock 10 $3.01 $30
Sale
CORMORANT ASSET MANAGEMENT, LP 10 percent owner
Class A Common Stock 10 $2.98 $30
Sale
CORMORANT ASSET MANAGEMENT, LP 10 percent owner
Class A Common Stock 280 $2.97 $832
Sale
CORMORANT ASSET MANAGEMENT, LP 10 percent owner
Class A Common Stock 398,600 $2.9 $1,155,940
Purchase
SCHALL THOMAS J. director Class A Common Stock 2,900 $2.55 $7,386
Purchase
FEINBERG PETER director
Class A Common Stock 25,000 $2.55 $63,725
Insider Compensation
Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D. (1982) Co-Founder, Pres, Chief Executive Officer & Director
$806,040
Dr. Brett M. Hall Ph.D. (1968) Chief Scientific Officer
$775,200
Dr. Scott Barrett M.D. (1963) Chief Medical Officer
$715,400
Thursday, 19 December 2024
globenewswire.com
Friday, 13 December 2024
benzinga.com
Thursday, 12 December 2024
globenewswire.com
Wednesday, 27 November 2024
globenewswire.com
Wednesday, 13 November 2024
globenewswire.com
Wednesday, 16 October 2024
zacks.com
Monday, 16 September 2024
zacks.com
Thursday, 12 September 2024
globenewswire.com
Tuesday, 6 August 2024
globenewswire.com
Thursday, 1 August 2024
investorplace.com
Wednesday, 31 July 2024
globenewswire.com
Tuesday, 9 July 2024
247wallst.com
Wednesday, 29 May 2024
globenewswire.com
Tuesday, 7 May 2024
globenewswire.com
Monday, 6 May 2024
globenewswire.com
Tuesday, 9 April 2024
globenewswire.com
Wednesday, 3 April 2024
globenewswire.com
Wednesday, 27 March 2024
globenewswire.com
Tuesday, 19 March 2024
Seeking Alpha
Monday, 18 March 2024
Zacks Investment Research
Tuesday, 5 March 2024
GlobeNewsWire
Thursday, 1 February 2024
GlobeNewsWire
Monday, 20 November 2023
GlobeNewsWire
Wednesday, 4 October 2023
GlobeNewsWire
Wednesday, 6 September 2023
GlobeNewsWire
Friday, 7 July 2023
Seeking Alpha
Wednesday, 5 July 2023
Zacks Investment Research
Tuesday, 30 May 2023
GlobeNewsWire
Thursday, 4 May 2023
Zacks Investment Research
Wednesday, 12 April 2023
GlobeNewsWire
  • What's the price of Immuneering stock today?

    One share of Immuneering stock can currently be purchased for approximately $3.38.

  • When is Immuneering's next earnings date?

    Unfortunately, Immuneering's (IMRX) next earnings date is currently unknown.

  • Does Immuneering pay dividends?

    No, Immuneering does not pay dividends.

  • How much money does Immuneering make?

    Immuneering has a market capitalization of 63.03M. Immuneering made a loss 53.47M US dollars in net income (profit) last year or -$0.49 on an earnings per share basis.

  • What is Immuneering's stock symbol?

    Immuneering Corporation is traded on the NASDAQ under the ticker symbol "IMRX".

  • What is Immuneering's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Immuneering?

    Shares of Immuneering can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Immuneering's key executives?

    Immuneering's management team includes the following people:

    • Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D. Co-Founder, Pres, Chief Executive Officer & Director(age: 43, pay: $806,040)
    • Dr. Brett M. Hall Ph.D. Chief Scientific Officer(age: 57, pay: $775,200)
    • Dr. Scott Barrett M.D. Chief Medical Officer(age: 62, pay: $715,400)
  • Is Immuneering founder-led company?

    Yes, Immuneering is a company led by its founder Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D..

  • How many employees does Immuneering have?

    As Jul 2024, Immuneering employs 65 workers, which is 4% less then previous quarter.

  • When Immuneering went public?

    Immuneering Corporation is publicly traded company for more then 4 years since IPO on 30 Jul 2021.

  • What is Immuneering's official website?

    The official website for Immuneering is immuneering.com.

  • Where are Immuneering's headquarters?

    Immuneering is headquartered at 245 Main Street, Cambridge, MA.

  • How can i contact Immuneering?

    Immuneering's mailing address is 245 Main Street, Cambridge, MA and company can be reached via phone at +61 75008080.

Immuneering company profile:

Immuneering Corporation

immuneering.com
Exchange:

NASDAQ

Full time employees:

66

Industry:

Biotechnology

Sector:

Healthcare

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

245 Main Street
Cambridge, MA 02142

CIK: 0001790340
ISIN: US45254E1073
CUSIP: 45254E107